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Katja R. Turner, MD,* Nicholas C. Joseph,* and Emile G. Daoud, MD‡Background: To date, general anesthesia has been sug-
gested as the preferred approach for implantation of a
subcutaneous implantable cardioverter-deﬁbrillator (S-ICD).
The purpose of this study was to assess the use of
monitored anesthesia care (MAC) for S-ICD implantation.
The goals were to assess adequate sedation and analgesia
(efﬁcacy endpoints) and major perioperative airway or
hemodynamic compromise (safety endpoints). The authors
hypothesized that MAC may provide adequate sedation and
analgesia and no major perioperative airway or hemody-
namic compromise during S-ICD implantation and multiple
deﬁbrillation threshold (DFT) testing.
Methods: Prospectively collected data of patients who
underwent S-ICD implantation with MAC from 2015 to
2016 were analyzed retrospectively. The efﬁcacy end-
points were the provision of an optimal depth of sedation
and analgesia to facilitate S-ICD implantation without
intra-procedure patient discomfort or awareness, and the
absence of “severe” pain at the lead tunneling and the
generator insertion sites post-procedure. The safety end-
points included: (1) periprocedural hypotension, as deﬁned
by a mean arterial pressure (MAP) o 60 mmHg refractory
to conventional pharmacotherapy, (2) heart rate (HR) o 45
bpm requiring pharmacologic support, and (3) sedation-
induced airway compromise requiring endotracheal
intubation.
Measurements: MAP and HR were recorded during S-ICD
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Journal of Cardiothoracicinfusion rates of propofol, supplemental sedatives, and
analgesics, and doses of vasopressor and/or inotropic
agents administered intra-procedurally were recorded.
Post-procedure pain scores also were noted.
Results: Ten patients underwent S-ICD implantation with
MAC (mean age, 56 years; 50% men; mean left ventricular
ejection fraction was 39%). Implantation of the S-ICD system
using MAC was successful in all patients without any major
adverse events. The mean baseline MAP was 92.8 mmHg,
and the mean end-procedure MAP was 88 mmHg (p ¼ 0.26).
When compared to baseline and end-procedure, the mean
lowest intra-procedure MAP was signiﬁcantly lower (67.4
mmHg; p ¼ 0.0001). The mean baseline HR was 65.7 bpm,
and the mean end-procedure HR was 70.1 bpm (p ¼ 0.28).
When compared to baseline and end-procedure, the mean
lowest intra-procedure HR was signiﬁcantly lower (55.8
bpm; po 0.001). MAC was not associated with airway
compromise in any patient, and post-procedure pain was
rated as no greater than “mild”.
Conclusions: Among a heterogeneous patient population
undergoing S-ICD implantation and DFT testing, the use of
MAC is efﬁcacious, feasible, and safe.
& 2016 The Authors. Published by Elsevier Inc. All rights
reserved.
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deﬁbrillator, deﬁbrillation threshold testing, monitored
anesthesia care, depth of sedation, general anesthesiaTHE SUBCUTANEOUS IMPLANTABLE cardioverter-deﬁbrillator (S-ICD) system is composed of a pulse
generator and a single subcutaneous electrode, and was
developed as a substitute for conventional transvenous ICD
systems.1–3 It has demonstrated efﬁcacy and safety in the
management of malignant ventricular arrhythmias, and
currently is being implanted globally at an accelerated
rate.1–5 The two largest clinical trials, the S-ICD IDE study
and the EFFORTLESS study, involved the use of general
anesthesia (GA),3,4 and most anesthesiologists consider GA
the preferred method for S-ICD implantation due to the
extensive dissection and tunneling, multiple deﬁbrillationthreshold (DFT) testing of induced ventricular ﬁbrillation
(VF), and attendant cardiovascular depression associated with
DFT testing.6 However, a recent study reported signiﬁcant
reductions in blood pressure and heart rate (HR), requiring
pharmacotherapy, and related to GA during S-ICD implanta-
tion and DFT testing.6 Monitored anesthesia care (MAC) may
avert these hemodynamic changes.7
The purpose of this study, therefore, was to describe
outcomes when using MAC during S-ICD implantation. The
hypothesis of this study was that MAC would provide
adequate sedation and analgesia (efﬁcacy endpoints) and
no major perioperative airway or hemodynamic compromise
(safety endpoints) during S-ICD implantation and DFT
testing.MATERIALS AND METHODS
Study Design
This was a single-center, non-randomized descriptive study
of outcomes in 10 patients undergoing S-ICD implantation for
Class I or II indications with MAC at The Ohio State
University Wexner Medical Center between January 2015
and January 2016. Patients were identiﬁed through a retro-
spective analysis of prospective S-ICD database. The study was
approved by the local institutional review board.and Vascular Anesthesia, Vol 30, No 5 (October), 2016: pp 1228–1233
Table 1. Clinical Characteristics of S-ICD Patients
Characteristics Patients (n ¼ 10)
ASA physical status classiﬁcation
ASA II 1 (10.0%)
ASA III 2 (20.0%)
ASA IV 7 (70.0%)
Demographic characteristics
Age (yr) 55.90  16.13
Male sex 5 (50.0%)
BMI (kg/m2) 28.47  9.57
LVEF (%) 39.05  0.15
Patients with EF r30% 5 (50.0%)
Indication for S-ICD implantation
Primary prevention of sudden cardiac death 7 (70.0%)
Secondary prevention of sudden cardiac death 3 (30.0%)
Medical history
Atrial ﬁbrillation/atrial ﬂutter 2 (20.0%)
Chronic kidney disease 1 (10.0%)
Congestive heart failure 7 (70.0%)
Coronary artery bypass graft 1 (10.0%)
Coronary artery disease 6 (60.0%)
Diabetes mellitus 2 (20.0%)
Hypertension 6 (60.0%)
Ischemic cardiomyopathy 5 (50.0%)
Non-ischemic cardiomyopathy 3 (30.0%)
Pulmonary hypertension 2 (20.0%)
Previous transvenous ICD 3 (30.0%)
Previous myocardial infarction 5 (50.0%)
Left ventricular assist device 1 (10.0%)
Torsades de pointes 1 (10.0%)
Ventricular tachycardia 3 (30.0%)
Outpatient medications*
ACE inhibitors 4 (40.0%)
Amiodarone 1 (10.0%)
Angiotensin receptor blockers 2 (20.0%)
Aspirin 5 (50.0%)
Beta blockers 9 (90.0%)
Diuretics 7 (70.0%)
Warfarin 3 (30.0%)
Abbreviations: ACE, angiotensin-converting enzyme; ASA, Amer-
ican Society of Anesthesiologists; BMI, body mass index; LVEF, left
ventricular ejection fraction; S-ICD, subcutaneous implantable cardi-
overter deﬁbrillator.
*Some patients took multiple medications.
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The efﬁcacy endpoints consisted of the following: (1) the
provision of an optimal depth of sedation and analgesia to
facilitate S-ICD implantation without intra-procedure patient
discomfort or awareness; and (2) the absence of “severe” pain
at the lead tunneling and generator insertion sites post-
procedure.8 The safety endpoints included: (1) periprocedural
hypotension, as deﬁned by a mean arterial pressure (MAP)
o 60 mmHg refractory to conventional doses of inotropic or
vasopressor support, (2) HRo 45 bpm requiring chronotropic
therapy, and (3) sedation-induced airway compromise requiring
endotracheal intubation.8–10
Pre-Procedure
All S-ICD implantations were performed under the guidance
of a cardiovascular anesthesiologist per institutional protocol.
The decision to use MAC for S-ICD implantation was made in
the electrophysiology laboratory pre-procedure holding area
after consultation with the implanting electrophysiologist and
following evaluation of the patient. The main considerations in
selecting MAC were to avoid potential airway compromise,
aspiration, and cardiovascular collapse.8,10,11 A myriad of
factors were considered in the decision-making process, as
per the American Society of Anesthesiologists (ASA) recom-
mendations for MAC, inclusive of but not limited to: distorted
head and neck anatomy predictive of intubation difﬁculty,
history of difﬁcult intubation, poorly controlled gastroesopha-
geal reﬂux disease, obesity, history of obstructive sleep apnea,
history of moderate-to-severe pulmonary hypertension, baseline
hemodynamics, and the inability to have direct access to the
patient’s airway during the procedure.10,11 Patients with the
aforementioned conditions were considered poor candidates for
MAC, and subsequently underwent S-ICD implantation under
GA. Furthermore, the majority of outpatient cardiovascular
medications were continued in the perioperative period in order
to avoid potential exacerbation of baseline cardiac disease.
Continued medications were inclusive of beta-blockers, aspirin,
diuretics, angiotensin-converting enzyme inhibitors, and angio-
tensin-receptor blocking agents (Table 1).
Intra-Procedure
S-ICD system implantation procedures were performed in
an electrophysiology laboratory equipped with anesthesia
equipment. All monitoring was completed noninvasively. After
appropriate patient positioning, supine with the left arm
extended away from the body, continuous monitoring was
initiated with pulse oximetry, capnography, and electrocardio-
graphy.11 Noninvasive blood pressure measurements, respira-
tory rate, and hemodynamic variables were recorded electroni-
cally at least every 5 minutes. Supplemental oxygen was
administrated using a MAC-safe nasal cannula or a simple
facemask with a capnography attachment. The baseline MAP
and HR, recorded prior to the initiation of sedation, were
compared to the lowest intra-procedure value and the ﬁnal
intra-procedure value for each patient.
Propofol infusion was used in all patients, with a mean
minimum infusion rate of 42  13.08 μg/kg/min and a mean
maximum infusion rate of 107.50  42.09 μg/kg/min. Thepropofol infusion was supplemented with other sedatives and/
or analgesics in a limited number of patients. Five patients
received midazolam (mean dose of 3.60  2.33 mg), four
patients received fentanyl (mean dose of 87.50  21.65 μg),
and two patients received ketamine (mean dose of 50  0 mg).
At the pulse generator insertion site and at the inferior margin
of the xiphoid process, the electrophysiologists injected 1%
lidocaine subcutaneously for analgesia.
The S-ICD implantation procedure is well described.6,12 In
summary, a pulse generator (A209 EMBLEM model, Boston
Scientiﬁc, Marlborough, MA) is implanted in a subcutaneous
pocket created at the level of the sixth intercostal space along the
left anterior-axillary line. Considering that the pulse generator
pocket was created after the inﬁltration of local anesthesia, this
period required mild-to-moderate sedation in the study patients. A
S-ICD electrode (Q-TRAK, Boston Scientiﬁc, Marlborough,
MA) was then implanted subcutaneously from the pulse generator
ESSANDOH ET AL1230pocket medially to the inferior margin of the xiphoid process and
further tunneled cranially along the left parasternal border towards
the sternal notch.6 In this study, tunneling of the deﬁbrillator lead
required deep sedation due to the inability to inﬁltrate local
anesthesia along the entire path of the lead.
Deﬁbrillation testing was performed at the discretion of the
electrophysiologist and was completed in seven patients with
deep sedation to prevent awareness. Through the S-ICD, VF was
induced and then S-ICD performance, detection and successful
deﬁbrillation of VF, were monitored. If the S-ICD shock therapy
was unsuccessful in restoring sinus rhythm, the patient was
rescued with a transcutaneous biphasic shockZ 300 J. In the
event a patient experienced hypotension during DFT testing,
incremental doses of inotropic/vasopressor agents with phenyl-
ephrine, epinephrine, or ephedrine were administered at the
discretion of the anesthesiologist. Deﬁbrillation threshold testing
was not performed in three patients due to limitations identiﬁed
by the electrophysiologist.
The propofol infusion was discontinued at the end of the
procedure, and the patients were thereafter transferred to the
post-anesthesia care unit after the full return of consciousness.
Post-Procedure
In the post-anesthesia care unit, the following parameters
were monitored: vital signs, oximetry, telemetry, and pain
scores. Incisional pain at the lead tunneling site and the S-ICD
generator insertion site was graded by the patient using a 4-
point verbal pain scale as “none,” “mild,” “moderate,” or
“severe.” Intravenous hydromorphone was the drug of choice
for postoperative pain control.
Statistical Analysis
SAS Statistical Software Version 9.4 (SAS Institute, Inc.,
Cary, NC) was used for data analysis. Continuous variables
were summarized as mean  standard deviation, and catego-
rical variables as frequency and percentage. Continuous vari-
ables were compared using a Student’s t-test for pairedFig 1. (A) Variations in mean arterial pressure (MAP) during S-ICD im
bars represent 95% conﬁdence intervals. (B) Variations in heart rate (HR) d
HR and the bars represent 95% conﬁdence intervals.samples. Categorical variables were compared using a Chi-
Square Analysis.
RESULTS
Patient Population Demographics and Baseline
Characteristics
Between January 2015 and January 2016, 35 patients
underwent S-ICD implantation at the authors’ institution, 10
of which were performed with MAC (Table 1). The 10 study
patients had a mean age of 55.90  16.13 years, and were
equally represented with respect to sex (50% males and 50%
females). The majority of the patients had an ASA classiﬁca-
tion of IV (70%). Furthermore, the mean body mass index was
28.47  9.57 kg/m2, and the mean left ventricular ejection
fraction (LVEF) was 39.05%  0.15%. Of note, ﬁve patients
(50%) had an LVEFr 30%, and one patient had a left
ventricular assist device implanted for end-stage left-heart
failure.
Intra-Procedure Safety and Efﬁcacy Outcomes
S-ICD implantation was accomplished successfully using
solely MAC without any major adverse events. Speciﬁcally,
there were no instances of refractory hypotension, signiﬁcant
bradycardia, or respiratory compromise requiring endotracheal
intubation. Furthermore, the implanting conditions provided by
MAC were adequate and facilitated timely S-ICD implantation,
without any signiﬁcant intra-procedure or post-procedure
patient discomfort. The mean intra-procedure duration was
131.40  26.05 minutes.
Hemodynamic Impact of MAC
The use of MAC was not associated with signiﬁcant
hemodynamic changes, with minimal requirement for pharma-
cologic support and no need for invasive blood pressure
monitoring. Among all patients, the mean baseline MAP
was 92.8 mmHg (95% CI: 82.77-102.83), and the meanplantation with MAC. The open circles represent mean MAP and the
uring S-ICD implantation with MAC. The open circles represent mean
MONITORED ANESTHESIA FOR S-ICD IMPLANTATION 1231end-procedure MAP was 88 mmHg (95% CI: 81.00-95.00; p ¼
0.26 compared to baseline). When compared to baseline and
end-procedure, the mean lowest intra-procedure MAP was
signiﬁcantly lower (67.4 mmHg, 95% CI: 59.08-75.72; p ¼
0.0001). The intra-procedure variations in MAP are demon-
strated in Figure 1A. Furthermore, only two patients (20%)
received vasopressors/inotropes to maintain a MAP Z 60
mmHg. Patient A received 5 μg of epinephrine, 10 mg of
ephedrine, and 15 mg of ephedrine at separate time points for
corresponding MAPs of 60 mmHg, 60 mmHg, and 55 mmHg,
respectively. Patient B received 100 μg of phenylephrine for an
MAP of 60 mmHg.
With respect to HR, there was no need for chronotropic
therapy. The mean baseline HR was 65.70 bpm (95% CI:
57.30-74.10), and the mean end-procedure HR was 70.10 bpm
(95% CI: 62.40-77.80; p ¼ 0.28 compared to baseline). When
compared to baseline and end-procedure, the mean lowest
intra-procedure HR was signiﬁcantly lower (55.80 bpm, 95%
CI: 50.03-61.57; po 0.001). The intra-procedure variations in
HR are demonstrated in Figure 1B.
Deﬁbrillation Threshold Testing Hemodynamics
In the seven patients who underwent DFT testing, VF was
induced a total of eight times (mean of 1.14  0.35 VF
inductions per patient). A total of eight deﬁbrillation shock
therapies were delivered, seven via the S-ICD, and one from an
external biphasic deﬁbrillator. For the ﬁrst DFT test, the mean
MAP pre-DFT (5 minutes before DFT test) was 70.71 mmHg
(95% CI: 64.61-76.82), the mean MAP at DFT (immediately
after VF shock conversion) was 89.14 mmHg (95% CI: 78.67-
99.61), and the mean MAP post-DFT (5 minutes after DFT
test) was 85.71 mmHg (95% CI: 78.92-92.50). The changes in
MAP during DFT are depicted in Figure 2A. The mean HR
pre-DFT was 67 bpm (95% CI: 53.09-80.91), the mean HR at
DFT was 72.57 bpm (95% CI: 54.80-90.34), and the mean HR
post-DFT was 71.57 bpm (95% CI: 57.98-85.16). The changes
in HR during DFT are shown in Figure 2B. Following DFT
testing, there were increases in both MAP and HR in each ofFig 2. (A) Mean arterial pressure (MAP) pre-, at, and 5 minutes post-
circles represent mean MAP and the bars represent 95% conﬁdence interv
ﬁrst DFT. The open circles represent mean HR and the bars represent 95the 7 patients, and there was no need for pharmacologic
support.
Post-Procedure
All the study patients had a rapid recovery in the post-
anesthesia care unit without any adverse events. The highest
pain score was “mild.”
DISCUSSION
Main Findings
This study represented the ﬁrst series describing the use of
MAC in high-risk patients undergoing S-ICD implantation. The
main ﬁndings of this study were: (1) S-ICD implantation and
DFT testing could be accomplished safely using MAC with the
guidance of an anesthesiologist and an electrophysiologist
without any major hemodynamic deterioration or respiratory
compromise; and (2) MAC was efﬁcacious for S-ICD
implantation.
Hemodynamics
Considering that the occurrence of hypotension
(MAPo 60 mmHg) during non-cardiac surgery has been
associated with signiﬁcant morbidity and mortality, the primary
anesthetic concern during S-ICD implantation and DFT testing
is the maintenance of adequate MAP and HR.7,9,13,14 Further-
more, in comparison to MAC, the degree of hypotension has
been reported higher using GA with volatile anesthetics.7 In
this series, despite a patient population with extensive cardio-
vascular disease (5 patients had an LVEFo 30% and 7
patients had an ASA score of IV), only 1 patient developed
important hypotension (MAP o 60 mmHg) that was treated
with a single dose of ephedrine, 15 mg. Also, DFT testing was
associated with increases in MAP and HR, and no patient
developed hypotension in the post-anesthesia care unit.
In the authors’ prior publication, the use of GA was
associated with signiﬁcant hypotension in more than 50% of
the patients.6 Possible reasons for this greater incidence ofdeﬁbrillation threshold (DFT) testing for the ﬁrst DFT test. The open
als. (B) Heart rate (HR) pre-, at, and 5 minutes post-DFT testing for the
% conﬁdence intervals.
ESSANDOH ET AL1232hypotension compared to the current study were that the number
of delivered shocks was greater (3  2.9 shocks per patient), and
the intra-procedure duration was longer (186.2  54.1 minutes),
as well as the negative impact of volatile anesthetics on
myocardial contractility and vasomotor tone.6,7Anesthesia
As described by the ASA, MAC represents a continuum of
anesthesia care, from the awake state to potential GA without
intubation.15,16 As such, during S-ICD implantation and DFT
testing with MAC, the depth of anesthesia was adjusted to ensure
optimal implanting conditions for the electrophysiologist (ie,
avoidance of patient movement or patient discomfort) and the
prevention of patient awareness, especially during DFT testing).
Considering that the pulse generator pocket was created after the
inﬁltration of local anesthesia, this period required mild-to-
moderate sedation. Tunneling of the deﬁbrillator lead (the most
stimulating aspect of S-ICD implantation) required deep sedation
due to the inability to inﬁltrate local anesthesia along the entire
path of the lead. Furthermore, DFT testing also required deep
sedation to prevent patient awareness. Notably, all the study
patients denied intraoperative awareness post-procedure, and
tolerated device implantation and DFT testing well.
A propofol infusion is ideal for this type of procedure, in
which the bulk of the procedure requires mild-to-moderate
sedation and, only when deeper sedation is required for the
total 1- to 2-minute tunneling procedures and DFT testing, then
the propofol infusion is increased brieﬂy. Additionally, the
rapid onset and offset of propofol sedation enable the main-
tenance of spontaneous respirations during the procedure,
without the need for endotracheal intubation.10,11Limitations
This was a single-center observational study with a small
sample size (n = 10) and without a control group. As such,
the generalizability of the authors’ results is limited.
However, the data presented were collected prospectively
and recorded automatically in the electronic medical record,
thus reﬂecting accurate outcomes. Although the protocol
for MAC was not standardized, the care provided was
consistent with expected care with MAC as directed by
experienced anesthesiologists and tailored to the patient
characteristics.
CONCLUSIONS
To date, studies supported GA as the anesthetic of choice
to manage patients undergoing S-ICD implantation. However,
considering the novel nature of the S-ICD, the best anesthetic
choice remains undeﬁned. This study was the ﬁrst series to
report outcomes using MAC for S-ICD procedures. Among a
heterogeneous patient population with major cardiovascular
disease and other comorbidities undergoing S-ICD implanta-
tion and DFT testing, MAC, provided by an experienced
anesthesiologist, was demonstrated to be safe and efﬁcacious.
There were no important reductions in MAP or HR and no
requirements for intubation, as well as excellent management
of procedure pain. These results suggested that MAC can be
considered as an alternative to GA when applied to carefully
selected patients who are free from obesity, gastroesophageal
reﬂux disease, non-reassuring airway status, sleep apnea,
unstable baseline hemodynamics, and pulmonary hyperten-
sion. Ongoing randomized studies will provide further insight
into outcomes using MAC in comparison to GA for S-ICD
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